Comparison of Efficacy and Safety of Azilsartan and Olmesartan in Patients With Essential Hypertension

International Heart Journal
Yuhei ShigaKeijiro Saku

Abstract

Many patients still have high blood pressure (BP) after treatment with angiotensin II type 1 (AT1) receptor blockers (ARBs). We compared the efficacy and safety of azilsartan to those of olmesartan in a prospective randomized clinical trial. Sixty-four hypertensive patients who were treated with ARBs other than azilsartan and olmesartan were enrolled in this study. We randomly assigned patients to changeover from their prior ARBs to either azilsartan or olmesartan, and followed the patients for 3 months. Systolic BP (SBP) in the azilsartan group was significantly decreased at 3 months, and diastolic BP (DBP) and pulse rate (PR) in the olmesartan group showed significant reductions after 3 months. There were no significant differences in ΔSBP, ΔDBP, or ΔPR (Δ = the value at 3 months minus the value at 0 months) between the groups. Serum levels of creatinine (Cr), uric acid (UA), and potassium (K) in the azilsartan group significantly increased after 3 months. While the changes in Cr, UA, and K were within the respective normal ranges, ΔSBP was positively associated with ΔCr in the azilsartan group. In conclusion, there was no difference in the depressor effects of azilsartan and olmesartan, and there were no serious changes in b...Continue Reading

References

Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
May 28, 2004·Pharmacotherapy·Benjamin J Epstein
Oct 18, 2006·The Journal of Pharmacology and Experimental Therapeutics·Takashi IwanagaIkumi Tamai
Jul 7, 2010·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Shin-ichiro MiuraKeijiro Saku
Jul 30, 2010·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masahiro FujinoKeijiro Saku
Dec 3, 2010·The Journal of Pharmacology and Experimental Therapeutics·Mami OjimaHideaki Nagaya
Jan 29, 2011·The Journal of Clinical Hypertension·George L BakrisStuart Kupfer
Mar 20, 2012·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Yuhei ShigaKeijiro Saku
Oct 5, 2012·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shin-ichiro MiuraKeijiro Saku
Nov 28, 2012·Current Pharmaceutical Design·Satoshi ImaizumiKeijiro Saku
Aug 22, 2014·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Yuhei ShigaKeijiro Saku
Nov 10, 2015·International Heart Journal·Yuichi IkedaIssei Komuro
Apr 19, 2016·Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia·Akira SezaiHisakuni Sakino

❮ Previous
Next ❯

Citations

Oct 30, 2018·International Heart Journal·Hiroaki IchikawaHirofumi Tomita
Aug 9, 2019·Journal of Pharmacy Practice·Elizabeth M Sutton BurkeAngela K Nagel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.